- Senior Investigator, Immunopathogenesis Section
Dr. Wynn is a senior investigator and chief of the Immunopathogenesis Section of the Laboratory of Parasitic Diseases. He also serves as the scientific director of the NIH-Oxford-Cambridge Scholars program, a doctoral training program for outstanding science students committed to biomedical research, which annually supports more than 64 doctoral candidates at NIH, Oxford University, and Cambridge University. Dr. Wynn obtained his Ph.D. from the University of Wisconsin-Madison Medical School in the department of microbiology and immunology. His laboratory group uses in vivo model systems to study the immunological mechanisms of inflammation and fibrosis. He has published over 200 papers, reviews, and book chapters in many prestigious journals, including Nature, Nature Immunology, Journal of Experimental Medicine, Gastroenterology, Nature Reviews Immunology, Nature Medicine, and Annual Review of Immunology. He has made important contributions to our understanding of the role of IL-13, IL-17A, and macrophages in the pathogenesis of fibrosis in multiple organ systems and has developed clinically relevant models to test novel anti-fibrotic drugs. His group collaborates extensively with the pharmaceutical industry to accelerate the translation of basic science discoveries into novel treatments for patients. Dr. Wynn was elected to fellowship in the American Academy of Microbiology in 2013 and has received several prestigious awards, including the Bailey K. Ashford Medal from the American Society of Tropical Medicine and Hygiene, the Oswaldo Cruz Medal from the Oswaldo Cruz Foundation, and two Merit Awards from NIH. Dr. Wynn has organized several national and international scientific meetings, including three Keystone Symposia and the first Aegean conference on Tissue Repair, Regeneration, and Fibrosis.
- (2020). Opinion on Immune Tolerance Therapeutic Development. TOXICOLOGIC PATHOLOGY. 48(6), 712-717.
- (2020). Metformin and 2-Deoxyglucose Collaboratively Suppress Human CD4(+) T Cell Effector Functions and Activation-Induced Metabolic Reprogramming. JOURNAL OF IMMUNOLOGY. 205(4), 957-967.
- (2019). Anti-IL-13R alpha 2 therapy promotes recovery in a murine model of inflammatory bowel disease. Mucosal Immunology. 12(5), 1174-1186.
- (2019). Fibroblast-specific integrin-alpha V differentially regulates type 17 and type 2 driven inflammation and fibrosis. JOURNAL OF PATHOLOGY. 248(1), 16-29.
- (2019). Heat shock protein 70 is a positive regulator of airway inflammation and goblet cell hyperplasia in a mouse model of allergic airway inflammation. JOURNAL OF BIOLOGICAL CHEMISTRY. 294(41), 15082-15094.